Posted by Michael Wonder on 28 Oct 2022
Health Canada approves Rebinyn (coagulation factor IX (recombinant), pegylated) for the treatment of routine prophylaxis to prevent or reduce frequency of bleeding episodes in children with haemophilia B
27 October 2022 - Expanded indication for Rebinyn will continue to support Canadian paediatric patients living with haemophilia B.
Novo Nordisk announced today that Health Canada has approved a new indication for Rebinyn (coagulation factor IX (recombinant), pegylated) for the treatment of routine prophylaxis in haemophilia B patients that are <18 years of age.
